Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
In the recent past, concerns have raised regarding the potential risk of acute pancreatitis among type 2 diabetic patients using incretin-based drugs such as glucagon-like peptide 1 (GLP-1) analogs and dipeptidyl peptidase 4 (DPP-4) inhibitors. The aim of this study is to investigate the association between exposure to incretin-based drugs and the occurrence of pancreatitis reported in the French Pharmacovigilance Database. The case/non-case method was performed from serious adverse drug reactions (ADRs) involving antihyperglycemic agents (except insulin alone) reported to the French pharmacovigilance system between March 2008 (first marketing of an incretin-based drug in France) and March 2013. Cases were defined as reports of pancreatitis, and all other serious ADRs were considered non-cases. Disproportionality was assessed by calculating reporting odds ratios (ROR) adjusted for age, gender, history of pancreatitis, other antihyperglycemic drugs and other drugs associated with a higher risk of pancreatitis. Among 3,109 serious ADRs, 147 (4.7 %) reports of pancreatitis were identified as cases and 2,962 reports (95.3 %) of other ADRs as non-cases. Among the cases, 122 (83.0 %) involved incretin-based drugs. Disproportionality was found for all incretin-based drugs (adjusted ROR: 15.7 [95 % CI 9.8-24.9]), all GLP-1 analogs (29.4 [16.0-53.8]), exenatide (28.3 [12.8-62.3]), liraglutide (30.4 [15.4-60.0]), all DPP-4 inhibitors (12.1 [7.3-20.0]), sitagliptin (12.4 [7.3-21.0]), saxagliptin (15.1 [4.3-52.7]), and vildagliptin (7.4 [3.1-17.6]). Temporal analysis found disproportionality for incretin-based drugs since their first year of marketing in France. Compared with other antihyperglycemic agents, use of incretin-based drugs is associated with an increased risk of reported pancreatitis in France.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, GLP-1RAs use may be associated with an increased risk of acute pancreatitis and thyroid cancer, and the FDA has warned the public about these AEs (10–12).”
From Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (2022) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 1×
“Recently, two large randomized controlled trials did not find any increased pancreatitis risk with saxagliptin and alogliptin [34, 35].”
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 1×
“Recently, two large randomized controlled trials did not find any increased pancreatitis risk with saxagliptin and alogliptin [34, 35].”
Under-Reporting of Adverse Drug Reactions: A Systematic Review
Hazell, L., & Shakir, S. A. W. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00003 · Cited by 1,931 · cited 1×
“Considering that the rate of pancreatitis associated with incretin-based drugs which are effectively reported to pharmacovigilance system could range from 5% to 20% [12], the 122 cases reported between 2008 and 2013 in France could hypothetically represent 610 to 2,440 actual cases.”
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 3×
“In order to study variation in reporting rate and the presence of a notoriety effect [11], we performed a year-by-year analysis and compared the RORs before and after March 2011 (when the first study suggesting a risk of pancreatitis in the FDA AERS database was published) [2].”
InfluentialQuantitative signal detection using spontaneous ADR reporting
Bate, A., & Evans, S. J. W. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1742 · Cited by 912 · cited 1×
“The ROR is used to compare the rate of exposure to incretin-based drugs in cases of pancreatitis versus that in non cases [8, 9].”
Montastruc, J., Sommet, A., Bagheri, H., & Lapeyre‐Mestre, M. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04037.x · Cited by 517 · cited 1×
“Despite the fact that the disproportionality approach cannot give quantitative risk assessment for a specific ADR (ROR cannot be interpreted as risk ratio), case/non case studies analyzing "real life" pharmacovigilance data have shown in the past to be useful to detect drug safety signals [24, 25].”
Self-citationSingh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467 · cited 1×
“68]) [41].”
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. L. (2009) · Diabetes Care · doi:10.2337/dc08-1755 · Cited by 435 · cited 1×
“Several studies showed an increased risk of pancreatitis in patients with type 2 diabetes suggesting a role of diabetes itself [21-23].”
Dore, D. D., Seeger, J. D., & Arnold Chan, K. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 326
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Case-non-case studies: principle, methods, bias and interpretation
Faillie, J.-L. (2019) · Therapies · doi:10.1016/j.therap.2019.01.006 · Cited by 336
Self-citationLiu, L., Chen, J., Wang, L., Chen, C., & Chen, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043789 · Cited by 258
Drug-induced acute pancreatitis: a review.
Jones, M. R., Hall, O. M., Kaye, A. M., & Kaye, A. D. (2015) · PubMed · Cited by 251
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., & Zhang, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.996179 · Cited by 145
Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus
Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0199-3 · Cited by 126
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Hu, N., Juurlink, D. N., Paterson, J. M., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1522 · Cited by 120
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1006625 · Cited by 126
Tkáč, I., & Raz, I. (2017) · Diabetes Care · doi:10.2337/dc15-1707 · Cited by 112
What is pharmacoepidemiology? Definition, methods, interest and clinical applications
Montastruc, J., Bénevent, J., Montastruc, F., Bagheri, H., Despas, F., Lapeyre‐Mestre, M., & Sommet, A. (2018) · Therapies · doi:10.1016/j.therap.2018.08.001 · Cited by 99
Self-citationThe pharmacokinetic considerations and adverse effects of DDP-4 inhibitors
Filippatos, T. D., Athyros, V. G., & Elisaf, M. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.907274 · Cited by 91
“Another study investigated the association between exposure to incretinbased drugs and the occurrence of pancreatitis using the French Pharmacovigilance Database [72].”
BackgroundInfluentialIncretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study
Faillie, J.-L., Azoulay, L., Patenaude, V., Hillaire-Buys, D., & Suissa, S. (2014) · BMJ · doi:10.1136/bmj.g2780 · Cited by 83
Self-citationGiorda, C. B., Sacerdote, C., Nada, E., Marafetti, L., Baldi, I., & Gnavi, R. (2014) · Endocrine · doi:10.1007/s12020-014-0386-8 · Cited by 75
Genuth, S. (2015) · Diabetes Care · doi:10.2337/dc14-0565 · Cited by 60
“Most, but not all (46), reviews and meta-analyses have not substanti-”
BackgroundLes études cas–non cas : principe, méthodes, biais et interprétations
Faillie, J. (2017) · Therapies · doi:10.1016/j.therap.2017.08.006 · Cited by 80
“[14] Faillie JL, Babai S, Crepin S, Bres V, Laroche ML, Le Louet H,”
BackgroundSelf-citationDrug-Induced Acute Pancreatitis: An Evidence-Based Classification (Revised)
Saini, J., Marino, D., Badalov, N. L., Vugelman, M., & Tenner, S. M. (2023) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000621 · Cited by 72
Huang, J., Jia, Y., Sun, S., & Meng, L. (2020) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-020-00447-w · Cited by 65
Diabetes Mellitus is Associated With Mortality in Acute Pancreatitis
Huh, J. H., Jeon, H., Park, S. M., Choi, E. H., Lee, G. S., Kim, J. W., & Lee, K. J. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000783 · Cited by 56
Giri, S., & Bader, A. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.011 · Cited by 67
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
Zhang, L., Mao, W., Liu, D., Hu, B., Lin, X., Ran, J., Li, X., & Hu, J. Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1231320 · Cited by 49
Alenzi, K. A. O., Alsuhaibani, D. S., Batarfi, B. S., & Alshammari, T. M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364110 · Cited by 52
Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0385-y · Cited by 42
Mathieu, C., Kozlovski, P., Novartis Pharma AG, B., Paldánius, P. M., Novartis Pharma AG, B., Foley, J. E., Modgill, V., Novartis Pharma AG, B., Evans, M., Șerban, C. I., et al. (2017) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2017.13.02.68 · Cited by 47
Gautier, J.-F., Martinez, L., Penfornis, A., Eschwège, E., Charpentier, G., Huret, B., Madani, S., & Gourdy, P. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0245-x · Cited by 40
Incretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
Antihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 30
Prospective evaluation of the aetiological profile of acute pancreatitis in young adult patients
Culetto, A., Bournet, B., Haennig, A., Alric, L., Péron, J., & Buscail, L. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.03.009 · Cited by 27
Incretin-Based Drugs and Adverse Pancreatic Events: Almost a Decade Later and Uncertainty Remains
Azoulay, L. (2015) · Diabetes Care · doi:10.2337/dc15-0347 · Cited by 27
Li, Q., Hou, C., Peng, Y., Zhu, X., Shi, C., Zhang, K., Tu, M., Guo, F., Huang, D., & Miao, Y. (2019) · BioMed Research International · doi:10.1155/2019/2620750 · Cited by 28
“Second, there is no information regarding additional factors that may have contributed to pancreaticrelated events such as GLP-1 receptor agonists and DPP-4 inhibitors [28, 29].”
BackgroundZhang, X., Wang, M., Wang, X., Zhu, Z., Zhang, W., Zhou, Z., Tang, W., & Li, Q. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.12.007 · Cited by 26
Gamble, J., Donnan, J. R., Chibrikov, E., Twells, L., Midodzi, W. K., & Majumdar, S. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-33483-y · Cited by 26
Sportiello, L., Rafaniello, C., Scavone, C., Vitale, C., Rossi, F., & Capuano, A. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.002 · Cited by 27
Chang, H., Hsieh, C.-F., Singh, S., Tang, W., Chiang, Y.-T., & Huang, W.-F. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3770 · Cited by 21
de Heer, J., & Göke, B. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.955013 · Cited by 21
“Similar results based on FAERS [76] as wells as the French Pharmacovigilance Database [77] were found in other studies with the same reservations applying.”
ResultGLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach
Crisci, I., Aragona, M., Politi, K. S., Daniele, G., & Prato, S. D. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0800-6 · Cited by 19
Tseng, C. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1091944 · Cited by 19
Psychiatric disorders, acne and systemic retinoids: comparison of risks
Moigne, M. L., Bulteau, S., Grall‐Bronnec, M., Gérardin, M., Fournier, J., Jonville‐Béra, A. ‐., Jolliet, P., Dréno, B., & Victorri‐Vigneau, C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1344641 · Cited by 18
Acute Pancreatitis in a Patient Taking Semaglutide
Patel, F. S., Gan, A., Chang, K., & Vega, K. J. (2023) · Cureus · doi:10.7759/cureus.43773 · Cited by 31
“However, other studies have shown conflicting results [17].”
ResultBuchtele, N., Schwameis, M., Schoergenhofer, C., Derhaschnig, U., Firbas, C., Karch, R., Nix, D., Schenk, R., & Jilma, B. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14208 · Cited by 14
Marshall, S., Ryan, E., Rivera, J. V., Reynolds, L. M., & Atti, S. K. (2024) · Journal of Medical Toxicology · doi:10.1007/s13181-024-01008-x · Cited by 11
Chen, S., Zhao, E., Li, W., & Wang, J. (2017) · Medicine · doi:10.1097/md.0000000000008952 · Cited by 12
“0) foracute pancreatitis associated with the use of DDP-4 inhibitors (sitagliptin, vildagliptin, and saxagliptin).([13]) A previous study([14]) found that DDP-4 inhibitors were associated with an increased risk of acute pancreatitis with anRRof 1.”
BackgroundHandelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01126-x · Cited by 12
Trends in the incidence of use of noninsulin glucose‐lowering drugs between 2006 and 2013 in France
Arnaud, M., Bezin, J., Bégaud, B., Pariente, A., & Salvo, F. (2017) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12298 · Cited by 11
Yoosuf, B. T., Muhammed Favas, K. T., Dutta, P. R., & Bansal, D. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2343015 · Cited by 9
Li, Z., Zhu, S., Huang, L., Shang, M., Yu, C., Zhu, H., Han, D., Huang, H., Yu, X., & Li, X. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.037 · Cited by 9
Leporini, C., Piro, R., Ursini, F., Maida, F., Palleria, C., Arturi, F., Pavía, M., Sarro, G. D., & Russo, E. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1246531 · Cited by 9
Vetter, M. L., Johnsson, K. M., Hardy, E., Wang, H., & Iqbal, N. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0627-1 · Cited by 7
First Reported Case of Dulaglutide-Induced Acute Pancreatitis With Normal Serum Lipase Level
Shahbazi, M., Qudsiya, Z., Fahel, A., Amini, A., & Tanoli, T. (2023) · Cureus · doi:10.7759/cureus.40576 · Cited by 5
“Exenatide, one of the first GLP1 agonists to be introduced, had 36 post-marketing reports of acute pancreatitis and was associated with a sixfold higher risk of pancreatitis compared to other diabetic medications in the first two years of use [14,15].”
BackgroundIncretin-based therapies and pancreatitis risk: myth or reality
Pappachan, J. M. (2014) · Endocrine · doi:10.1007/s12020-014-0490-9 · Cited by 6
Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes
Cahn, A., Cernea, S., & Raz, I. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9351-6 · Cited by 5
Exenatide Induces Impairment of Autophagy Flux to Damage Rat Pancreas
Li, Z., Huang, L., Yu, X., Yu, C., Zhu, H., Li, X., Han, D., & Huang, H. (2016) · Pancreas · doi:10.1097/mpa.0000000000000692 · Cited by 5
Qu’est-ce que la pharmacoépidémiologie?
Montastruc, J., Sommet, A., Montastruc, F., Moulis, G., Bagheri, H., Damase‐Michel, C., & Lapeyre‐Mestre, M. (2015) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30970-7 · Cited by 6
Self-citationThe risk of pancreatitis with sitagliptin therapy in older adults: a population-based cohort study
Clemens, K. K., McArthur, E., Fleet, J. L., HRAMIAK, I. M., & Garg, A. X. (2015) · CMAJ Open · doi:10.9778/cmajo.20140060 · Cited by 6
Li, G., Long, X., Pan, Y., Xiao, M., & Zhao, X. (2018) · Biomedical Research - India · doi:10.4066/biomedicalresearch.29-17-3436 · Cited by 4
Scientific report: a case of acute pancreatitis due to liraglutide
Quesada‐Vázquez, N. (2018) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2018.5912/2018 · Cited by 4
Inkretintengelyen ható antidiabetikumok és a pancreas betegségei (pancreatitis, pancreascarcinoma)
Jermendy, G. (2016) · Orvosi Hetilap · doi:10.1556/650.2016.30409 · Cited by 3
Sitagliptin related pancreatitis in the elderly: A rare but serious complication
Yen, J. M., Tan, L. F., & Sze, Y. L. (2017) · European Geriatric Medicine · doi:10.1016/j.eurger.2017.07.006 · Cited by 3
Kulenović, A., & Lagumdzija-Kulenovic, A. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101267 · Cited by 2
Gall bladder agenesis in Prader Willi syndrome
Jyotsna, V., Nair, A., Kandasamy, D., & Tripathi, M. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.149329 · Cited by 2
Pancreatitis in incretin-based therapies
Famularo, G., Morviducci, L., & Gasbarrone, L. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.11.007 · Cited by 1
Sun, Y. Q., Guo, C. Y., Li, Q., Guo, L., Chen, L., Wang, W., & Zhang, J. C. (2018) · Biomedical Research - India · doi:10.4066/biomedicalresearch.29-17-2708
“The FDA, as well as some experts has sent an alert for clinicians to realize the potential risk of Ex-4 use for pancreatitis [3,7,8,38].”
BackgroundDu, Q., Wang, Y., Yang, S., & Han, P. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s64691 · Cited by 1
Kabadi, U. M. (2017) · Advanced Research in Gastroenterology & Hepatology · doi:10.19080/argh.2017.03.555609 · Cited by 1
Insight in disease and drug interactions, with treatment optimisation of patients with cancer
Knapen (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20190510lk
Semaglutide induced Pancreatitis
Princy, R. (2024) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2024.v06i04.26238
“The proposed mechanism is pancreatic duct gland hyperplasia and acinar cell hypertrophy leading to exocrine occlusion, which in turn, may lead to pancreatic inflammation and vascular injury [7][8] .”
BackgroundUnmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance
Zinzi, A., Gaio, M., Ruggiero, R., Mascolo, A., Riemma, M. A., Cipriani, M., Laino, L. V., Berrino, L., Rossi, F., & Capuano, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1805842 · Cited by 1
“Literature data suggest that treatment with GLP-1 RAs is associated with an increased incidence of pancreatitis (Chis and Fodor, 1957; Li et al., 2014; Faillie et al., 2014).”
Sensitive issues of the incretin-based therapy
BAKULIN, I., Sukhomlinova, I. M., Lebedeva, Y., & BELOUSOV, A. (2026) · Медицинский вестник МВД · doi:10.52341/20738080_2026_142_3_25
Metadata
- Authors
- The French Pharmacovigilance Centers Network, Faillie, J.-L., Babai, S., Crépin, S., Bres, V., Laroche, M.-L., Le Louet, H., Petit, P., Montastruc, J.-L., & Hillaire-Buys, D.
- Affiliations
- Centre Hospitalier Universitaire de Montpellier (FR)
- Centre Hospitalier Universitaire de Limoges (FR)
- Inserm (FR)
- Corresponding author
- Faillie, Jean-Luc
- Venue
- Acta Diabetologica
- Published
- 2013-12-19
- Volume
- 51
- Issue
- 3
- Pages
- 491-7
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W2031272997
- Cited by
- 70
- References
- 35
- Citations by year
- 2026: 2 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 8 · 2015: 16 · 2014: 11
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- green
- unilim.hal.science
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Agence Nationale de Sécurité du Médicament et des Produits de Santé
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- acute pancreatitis, GLP-1 analogues, DPP-4 inhibitors, incretin-based drugs, type 2 diabetes, serious adverse drug reactions, exenatide, liraglutide, sitagliptin, saxagliptin, vildagliptin, pharmacovigilance, drug safety, antidiabetic drugs, reporting odds ratio
- MeSH terms
- Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Female, France, Humans, Male, Middle Aged, Pancreatitis, Case-Control Studies, Databases, Factual, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors, Pharmacovigilance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.